Anavex Life Sciences Corp. (NASDAQ: AVXL) Starts Presentation at 30th Annual ROTH Conference
Anavex Life Sciences (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company engaged in the development of drug candidates for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. ANAVEX®2-73, the company’s lead drug candidate, has successfully completed a phase 2 clinical trial for Alzheimer’s disease in which the drug exhibited the potential to treat additional CNS disorders, including epilepsy. Additionally, the company has received a research grant from the Michael J. Fox Foundation for Parkinson’s Research to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. The company’s product…







